BRIEF published on 01/24/2025 at 08:05, 1 year 3 months ago Median Technologies lève jusqu'à 47,5 millions d'euros pour le diagnostic du cancer du poumon par l'IA Banque Européenne D'investissement Technologies Médianes Eyonis™ Diagnostic Du Cancer Du Poumon Par IA Commercialisation Dans L'UE Et Aux États-Unis
PRESS RELEASE published on 01/24/2025 at 08:00, 1 year 3 months ago Inside Information / Other news releases Median Technologies secures up to €47.5 million for eyonis™ AI lung cancer diagnostic regulatory filings & U.S./EU commercialization. New financing & operational enhancements drive profitability & extend cash runway into Q4, 2025 AI Commercialization Median Technologies Lung Cancer Diagnostic Eyonis
PRESS RELEASE published on 01/24/2025 at 08:00, 1 year 3 months ago Informations privilégiées / Autres communiqués Median Technologies finalise des financements de 47,5 millions d'euros pour approuver et commercialiser eyonis™ LCS aux États-Unis et en Europe. Nouveaux prêts de la BEI et financement d'IRIS soutiennent le projet Financement IRIS Median Technologies BEI Eyonis LCS
BRIEF published on 11/26/2024 at 17:50, 1 year 5 months ago Median Technologies Showcases AI Lung Cancer Diagnostic at RSNA 2024 Clinical Trials Eyonis™ LCS RSNA 2024 AI-powered Diagnostics Lung Cancer Screening
BRIEF published on 11/26/2024 at 17:50, 1 year 5 months ago Median Technologies présente le diagnostic du cancer du poumon par IA au RSNA 2024 Essais Cliniques Eyonis™ LCS RSNA 2024 Diagnostics Basés Sur L'IA Dépistage Du Cancer Du Poumon
PRESS RELEASE published on 11/26/2024 at 17:45, 1 year 5 months ago Inside Information / Other news releases Median Technologies to showcase AI-powered lung cancer diagnostic eyonis™ LCS at RSNA 2024. Company presents latest developments and REALITY study results to experts in medical imaging conference AI-powered Median Technologies Eyonis LCS RSNA 2024 Lung Cancer Diagnostic
BRIEF published on 10/30/2024 at 17:50, 1 year 6 months ago Median Technologies et l'IA dans le dépistage du cancer du poumon Intelligence Artificielle Cancer Du Poumon Technologies Médicales Dépistage Médical Webconférence 2024
BRIEF published on 10/30/2024 at 17:50, 1 year 6 months ago Median Technologies and AI in lung cancer screening Artificial Intelligence Medical Technologies Lung Cancer Webconférence 2024 Medical Screening
PRESS RELEASE published on 10/30/2024 at 17:45, 1 year 6 months ago Informations privilégiées / Autres communiqués Median Technologies organise une webconférence sur l'Intelligence Artificielle dans le dépistage du cancer du poumon avec des leaders d'opinion. Étude REALITY eyonis™ LCS présentée le 7 novembre 2024. Intelligence Artificielle Dépistage Median Technologies Cancer Du Poumon Webconférence
BRIEF published on 10/07/2024 at 17:50, 1 year 7 months ago État des droits de vote et du capital de Median Technologies au 30 septembre 2024 Capital Droits De Vote Actions Median Technologies 30 Septembre 2024
Published on 05/23/2026 at 02:25, 8 minutes ago Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 8 minutes ago Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec
Published on 05/23/2026 at 01:00, 1 hour 33 minutes ago LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories
Published on 05/23/2026 at 00:55, 1 hour 38 minutes ago GLG Life Tech Corporation Reports 2026 First Quarter Financial Results
Published on 05/23/2026 at 00:15, 2 hours 18 minutes ago Molten Metals Completes Airborne Geophysical Survey at Texas Project
Published on 05/22/2026 at 22:05, 4 hours 28 minutes ago Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Published on 05/22/2026 at 22:05, 4 hours 28 minutes ago Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:51, 6 hours 42 minutes ago Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 05/22/2026 at 18:33, 8 hours ago Update on Coupon payment due on 23 May 2026 and Preparation of the Green Bond Restructuring
Published on 05/22/2026 at 18:30, 8 hours 3 minutes ago Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors
Published on 05/22/2026 at 19:35, 6 hours 58 minutes ago PROJET D'EVOLUTION DE SA GOUVERNANCE ET LA NOMINATION D'UN PRESIDENT DU DIRECTOIRE PAR INTERIM
Published on 05/22/2026 at 18:05, 8 hours 27 minutes ago Déclaration hebdomadaire d'opérations effectuées du 18 au 22 mai 2026
Published on 05/22/2026 at 18:05, 8 hours 27 minutes ago Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 13 hours 40 minutes ago Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
Published on 05/22/2026 at 12:52, 13 hours 40 minutes ago Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
